Skip to content

ROSA® Hip System THA PMCF

A Post-Market, Multi-Center, Single Arm Trial on Robotic Instrumentation (ROSA® Hip System) in Patients Undergoing Direct Anterior Total Hip Arthroplasty With Fluoroscopic Guidance

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05497206
Enrollment
12
Registered
2022-08-11
Start date
2024-06-05
Completion date
2024-12-20
Last updated
2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Avascular Necrosis of Hip, Osteoarthritis, Hip

Brief summary

This study is a Prospective, Multicenter, Single-Arm, Cohort post-market study to evaluate the accuracy of acetabular implant position using the robotic-arm surgical assistant (ROSA® Hip System).

Detailed description

Consecutive patients who meet all of the inclusion criteria and none of the exclusion criteria will be eligible for participation in the study, and will be pre-screened for participation in the informed consent process. The primary objective of this study is to assess the accuracy of acetabular implant position by evaluating the percentage of participants who are within the range of the Callanan safe zones for Acetabular Inclination (30 - 45 degrees). A patient is considered a success if their intra-operative and/or post-operative full pelvis fluoroscopic or radiographic images show the postoperative acetabular inclination to be within this safe zone range. Secondary Objectives include the evaluation of safety and efficacy of this system and will include the assessment of common adverse events, physical exam findings, radiologic results, and patient reported outcome measures. Data collection will occur at the following intervals: Pre-operative, Operative, 3-months, 1-year, and 2-years. Enrollment for the study is anticipated to last approximately 18 months. Allowing for 24 months of follow-up, the total estimated study time to final-patient final-visit will be approximately 42 months.

Interventions

DEVICEOne of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System

Total Hip Arthroplasty

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Inclusion: 1. Age 18 - 80 years 2. Body mass index ≤40 (BMI = kg/m2) 3. Patient is willing and able to provide informed consent 4. Patient qualifies for primary THA, via an anterior approach, due to osteoarthritis or avascular necrosis of the hip based on Investigator's clinical judgment 5. Independent of study participation, patient is a candidate and meets the indications and none of the contraindications for use with the ROSA Hip System Exclusion: 1. Has undergone an orthopaedic procedure of the spine or lower extremity, or is currently participating in a pain management clinical study of any joint, within the last 6 months or planned within the next 6 months 2. Patients receiving simultaneous bilateral hip arthroplasties are excluded from participation in this study; as well as any participants with staged bilateral arthroplasties within 6 months of each other 3. Active infection, sepsis, osteomyelitis 4. Patient is at a high risk for dislocation including those with long-segment spinal fusions (\>3 levels) and neuromuscular disorders 5. Inflammatory (rheumatoid or psoriatic arthritis) or post-traumatic arthropathy, or any other degenerative joint disease not consistent with osteoarthritis 6. Would, in the Investigator's opinion, be unwilling or unable to comply with the postoperative follow-up schedule 7. Patient is considered a member of a vulnerable population (pregnant, prisoner, mentally incompetent, etc.) 8. Previous hardware in the proximal femur or acetabulum from a prior orthopaedic procedure

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of implant position90 daysTo evaluate the accuracy of acetabular implant position using the robotic-arm surgical assistant (ROSA® Hip System) (rTHA). Accuracy of acetabular implant position will be assessed by evaluating the percentage of participants who are within the range of the Callanan safe zones for Acetabular Inclination (30 - 45 degrees). A patient is considered a success if their intra-operative and/or post-operative full pelvis fluoroscopic or radiographic images show the postoperative acetabular inclination to be within this safe zone range.

Secondary

MeasureTime frameDescription
Patient Reported Outcome Measure (Oxford Hip Score)24 monthsA questionnaire completed by the patient consisting of twelve questions that utilize a 5-point Likert scoring system (0 - 4) resulting in a score ranging from 0 (worst) to 48 (best).
Numeric Pain Rating Scale (NPRS)24 monthsAn 11-point NPRS is a patient self-completed reported outcome and will be used to assess the current level of pain for the affected hip. On this scale, 0 will indicate no pain and 10 will indicate the worst pain imaginable
Subject Satisfaction24 monthsA questionnaire consisting of a single satisfaction question in regard to the subjects hip replacement. Answers will include the following: Very Dissatisfied, Dissatisfied, Neutral, Satisfied, Very Satisfied.
Clinical performance will be assessed with evaluation of range of motion.24 monthsRange of motion will be evaluated in a supine position and assess flexion, abduction (in flexion), adduction (in flexion), external rotation (in extension), and internal rotation (in extension). Range of motion will be measured in degrees.
Evaluation of Patient safety24 monthsFrequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.
Clinical performance will be assessed by testing leg length discrepancy.24 monthsThis will be assessed by (3) categories (legs equal, right short, left short) and discrepancies will be measured in mm or cm.
Physician Radiographic Assessment of Acetabular Cup2 YearsRecords acetabular cup inclination (degrees), acetabular cup anteversion (degrees)
Physician Radiographic Assessment of Femoral and Global Offset and Leg Length Discrepancy2 YearsRecords femoral offset (mm), global offset (mm), leg length (mm)
Physician Radiographic Assessment of Significant Radiographic Findings2 YearsRecords evidence of fracture (y/n), evidence of acetabular migration (y/n), evidence of heterotopic ossification (y/n), or other significant radiographic findings (including the zone it occurs in)
Clinical performance will be assessed with evaluation of stability using the Trendelenburg test.24 monthsThe test is negative when the hip of the leg that is lifted, will also go up i.e., hiking of hip or the pelvis tilts upwards. The test is positive, when there is a drop of the hip or a downwards tilt of the pelvis. The test is level when the subject presents normal gait and adequate pelvic stability. If the subject is unable to perform the test, this will be noted unable to perform test.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026